RUBY - Rubius Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
RUBY price evolution
RUBY
| (in millions $) | 31 Jan 2023 | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $14.91 | $105.46 | $63.78 | $99.68 |
| Short term investments | $78.5 | $78.41 | ||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $20.2 | $110.82 | $143.49 | $180.04 |
| Long term investments | ||||
| Property, plant & equipment | $2.83 | $58.3 | $84.02 | $85.51 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $2.88 | $59.87 | $85.59 | $87.08 |
| Total investments | $78.5 | $78.41 | ||
| Total assets | $23.07 | $170.7 | $229.08 | $267.12 |
| Current liabilities | ||||
| Accounts payable | $1.23 | $8.72 | $12.44 | $12.08 |
| Deferred revenue | ||||
| Short long term debt | $1.1 | $9.21 | $9.15 | $9.08 |
| Total current liabilities | $7.94 | $32.62 | $30.99 | $28.92 |
| Long term debt | $101.49 | $102.48 | $103.45 | |
| Total noncurrent liabilities | $101.49 | $102.55 | $103.56 | |
| Total debt | $1.1 | $110.7 | $111.63 | $112.54 |
| Total liabilities | $7.94 | $134.11 | $133.54 | $132.47 |
| Shareholders' equity | ||||
| Retained earnings | -$856.68 | -$836.54 | -$773.67 | -$729.43 |
| Other shareholder equity | -$0.12 | -$0.06 | ||
| Total shareholder equity | $15.13 | $36.59 | $95.54 | $134.65 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $14.91 | $227.42 | $92.74 | $93.63 |
| Short term investments | $85.12 | $191.39 | ||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $20.2 | $229.82 | $181.51 | $289.27 |
| Long term investments | ||||
| Property, plant & equipment | $2.83 | $86.63 | $94.4 | $103.48 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $2.88 | $88.2 | $96.28 | $105.58 |
| Total investments | $85.12 | $191.39 | ||
| Total assets | $23.07 | $318.02 | $277.79 | $394.84 |
| Current liabilities | ||||
| Accounts payable | $1.23 | $11.57 | $5.48 | $7.18 |
| Deferred revenue | ||||
| Short long term debt | $1.1 | $9.02 | $8.95 | $10.54 |
| Total current liabilities | $7.94 | $34.66 | $27.84 | $33.76 |
| Long term debt | $104.44 | $107.71 | $86.46 | |
| Total noncurrent liabilities | $104.58 | $108.39 | $86.87 | |
| Total debt | $1.1 | $113.46 | $116.65 | $97 |
| Total liabilities | $7.94 | $139.24 | $136.23 | $120.63 |
| Shareholders' equity | ||||
| Retained earnings | -$856.68 | -$677.02 | -$480.47 | -$312.74 |
| Other shareholder equity | $0 | $0.07 | ||
| Total shareholder equity | $15.13 | $178.78 | $141.56 | $274.21 |
| (in millions $) | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $0.89 | $24.23 | $33 | $38.3 |
| Selling, general & administrative | $1.06 | $7.3 | $9.91 | $12.56 |
| Total operating expenses | $23.1 | $61.58 | $42.91 | $50.86 |
| Operating income | -$23.1 | -$61.58 | -$42.91 | -$50.86 |
| Income from continuing operations | ||||
| EBIT | -$21.27 | -$61.14 | -$42.61 | -$50.78 |
| Income tax expense | ||||
| Interest expense | -$1.13 | $1.74 | $1.63 | $1.63 |
| Net income | ||||
| Net income | -$20.14 | -$62.87 | -$44.24 | -$52.41 |
| Income (for common shares) | -$20.14 | -$62.87 | -$44.24 | -$52.41 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $96.41 | $141.59 | $116.11 | $112.42 |
| Selling, general & administrative | $30.84 | $53.03 | $50.34 | $57.18 |
| Total operating expenses | $178.45 | $194.62 | $166.45 | $169.6 |
| Operating income | -$178.45 | -$194.62 | -$166.45 | -$169.6 |
| Income from continuing operations | ||||
| EBIT | -$175.8 | -$190.11 | -$163.55 | -$160.87 |
| Income tax expense | ||||
| Interest expense | $3.86 | $6.43 | $4.18 | $2.59 |
| Net income | ||||
| Net income | -$179.67 | -$196.55 | -$167.73 | -$163.46 |
| Income (for common shares) | -$179.67 | -$196.55 | -$167.73 | -$163.46 |
| (in millions $) | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 |
|---|---|---|---|---|
| Net income | -$20.14 | -$62.87 | -$44.24 | -$52.41 |
| Operating activities | ||||
| Depreciation | $0.43 | $2.67 | $1.6 | $1.56 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | -$1.32 | $3.8 | $5.04 | $8.26 |
| Total cash flows from operations | -$32.52 | -$36.2 | -$34.29 | -$47.13 |
| Investing activities | ||||
| Capital expenditures | $17.68 | -$0.87 | -$1.76 | -$2.4 |
| Investments | $78.75 | -$78.44 | ||
| Total cash flows from investing | $17.68 | $77.88 | -$1.76 | -$80.85 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.16 | $0.08 | ||
| Net borrowings | -$75.7 | |||
| Total cash flows from financing | -$75.7 | $0.16 | $0.08 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$90.54 | $41.67 | -$35.89 | -$127.91 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$179.67 | -$196.55 | -$167.73 | -$163.46 |
| Operating activities | ||||
| Depreciation | $6.25 | $7.72 | $5.69 | $3 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $15.78 | $35.61 | $33.66 | $41.27 |
| Total cash flows from operations | -$150.14 | -$145.12 | -$127.65 | -$110.44 |
| Investing activities | ||||
| Capital expenditures | $12.64 | -$3.65 | -$5.5 | -$40.66 |
| Investments | $0.3 | $85 | $105.93 | -$91.98 |
| Total cash flows from investing | $12.94 | $81.35 | $100.43 | -$132.63 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.23 | $198.96 | $1.48 | $2.29 |
| Net borrowings | -$75.7 | -$0.15 | $25 | $25 |
| Total cash flows from financing | -$75.47 | $198.45 | $26.48 | $27.29 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$212.67 | $134.68 | -$0.73 | -$215.79 |
News
Fundamentals
| Market cap | $5.15M |
|---|---|
| Enterprise value | -$8.66M |
| Shares outstanding | 90.39M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$169.55M |
| EBIT | -$175.80M |
| Net Income | -$179.67M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.03 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | 0.05 |
| EV/EBIT | 0.05 |
| P/S ratio | N/A |
| P/B ratio | 0.34 |
| Book/Share | 0.17 |
| Cash/Share | 0.17 |
| EPS | -$1.99 |
|---|---|
| ROA | -104.16% |
| ROE | -254.93% |
| Debt/Equity | 0.52 |
|---|---|
| Net debt/EBITDA | 0.04 |
| Current ratio | 2.54 |
| Quick ratio | 2.54 |